News
(3)April 2026
AURA provides no substantive filing text for analysis
⚠️ Missing Document ⚠️ It looks like the actual content of the SEC filing for Aura Biosciences, Inc. is missing. I was provided with the form type and file name, but the PDF text itself was blank. To provide you with the deep, educational breakdown you expect—explaining the financials, the strateg
Aura Bioscience annual meeting votes directors and ratifies Ernst & Young auditor
# 🧾 What This Document Is 🤖 This is a Definitive Proxy Statement for the 2026 Annual Meeting of Stockholders. Think of this document as the rulebook for your annual meeting. Its entire purpose is to inform you about the important corporate decisions the board of directors wants you, the shareholde
March 2026
Aura Biosciences, Inc. — 8-K Filing
# 🧾 What This Document Is This is a **combined 8-K filing** and a press release where Aura Biosciences updates investors on its quarterly financial results and the progress of its clinical trials. Think of it as a "state of the union" for the company. It tells us how much money they spent, how much
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.